Several observational studies have investigated the association between RAAS inhibitor use and COVID-19 severity and outcomes. A retrospective analysis of 148 hypertensive COVID-19 patients found that ...

Renin–angiotensin–aldosterone system (RAAS) inhibitors are antihypertensive agents with conflicting results on protective effects against some types of cancer. In light of these controversies, we ...

In a recent study posted to the medRxiv* preprint server, researchers conducted an umbrella review and meta-analysis of the renin-angiotensin-aldosterone system (RAAS) inhibitors' impact on ...

A recent study posted to the medRxiv* preprint server investigated the association of renin-angiotensin-aldosterone system (RAAS)-mediated hypertension (HT) with coronavirus disease 2019 (COVID-19).

Treatments that target the renin-angiotensin-aldosterone system (RAAS) don’t improve outcomes in adult patients hospitalized with acute COVID-19. Three separate trials of different RAAS-related ...

Studies in animals have shown that ACE2 is used by coronaviruses as a functional receptor. ARBs and ACE inhibitors increase the expression of ACE2; a hypothesis that their use may modify ...

Please provide your email address to receive an email when new articles are posted on . Renin-angiotensin-aldosterone system (RAAS) inhibitors conferred reduced risks for starting dialysis or needing ...

"Patients who experience hyperkalemia while on RAAS inhibitor therapy may benefit from intensification of other evidence-based preventative measures against adverse cardiorenal outcomes, such as lipid ...

At one time, dual RAAS blockade was expected to provide more-complete inhibition of RAAS among patients with DKD. Results of large clinical trials dashed these hopes, finding increased risk of AKI and ...

What if there were a straightforward and relatively inexpensive way to lower the incidence of heart failure (HF), renal disease, stroke, and cognitive impairment? Cardiologist Bertram Pitt, MD, said ...